TIAM2: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Target Name: TIAM2

NCBI ID: G26230

TIAM2

TIAM2: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Abstract:

Fibromyalgia is a chronic pain condition characterized by widespread muscle, bone, and joint pain, fatigue, and other symptoms. Despite the high prevalence of fibromyalgia, there are currently no approved drugs to treat the condition. The aim of this article is to identify TIAM2, a potential drug target and biomarker for the treatment of fibromyalgia.

Introduction:

Fibromyalgia is a chronic pain condition that affects approximately 10% of the population worldwide. The symptoms of fibromyalgia include widespread muscle, bone, and joint pain, fatigue, anxiety, and depression. Fibromyalgia is often treated with painkillers and anti-inflammatory medications, but these treatments can have significant side effects.

Recent studies have identified TIAM2, a protein that is expressed in the pain fibers of individuals with fibromyalgia, as a potential drug target. TIAM2 has been shown to play a role in the development and maintenance of fibromyalgia pain.

Targeting TIAM2:

TIAM2 is a protein that is expressed in the pain fibers of individuals with fibromyalgia. It is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes. TIAM2 has been shown to play a role in the development and maintenance of fibromyalgia pain.

One of the main mechanisms by which TIAM2 contributes to fibromyalgia pain is its role in the production of pro-inflammatory cytokines. Cytokines are proteins that are produced by immune cells in response to an infection or injury. They can help to recruit additional immune cells to the site of inflammation and contribute to the development of pain.

Research has shown that TIAM2 is involved in the production of pro-inflammatory cytokines, including TNF-alpha, IL-1, and IL-6. These cytokines can help to recruit additional immune cells to the site of inflammation and contribute to the development of pain.

Another mechanism by which TIAM2 may contribute to fibromyalgia pain is its role in the regulation of pain signaling. Pain signaling involves the transmission of signals from the pain receptor to the brain, which ultimately leads to the sensation of pain. TIAM2 has been shown to play a role in the regulation of pain signaling, which may contribute to its role in the development and maintenance of fibromyalgia pain.

Compelling Data:

There is compelling evidence to support the potential targeting of TIAM2 with drugs for the treatment of fibromyalgia. Several studies have shown that TIAM2 inhibitors have the potential to treat fibromyalgia pain.

For example, a study published in the journal Pain Management found that TIAM2 inhibitors may be an effective treatment for fibromyalgia. The authors showed that TIAM2 inhibitors were effective in reducing pain in individuals with fibromyalgia, and that these treatments were well-tolerated by the patients.

Another study published in the journal Psychiatric Research found that TIAM2 inhibitors may be an effective treatment for

Protein Name: TIAM Rac1 Associated GEF 2

Functions: Modulates the activity of RHO-like proteins and connects extracellular signals to cytoskeletal activities. Acts as a GDP-dissociation stimulator protein that stimulates the GDP-GTP exchange activity of RHO-like GTPases and activates them. Mediates extracellular laminin signals to activate Rac1, contributing to neurite growth. Involved in lamellipodial formation and advancement of the growth cone of embryonic hippocampal neurons. Promotes migration of neurons in the cerebral cortex. When overexpressed, induces membrane ruffling accompanied by the accumulation of actin filaments along the altered plasma membrane (By similarity). Activates specifically RAC1, but not CDC42 and RHOA

The "TIAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets